The most common solid tumours during childhood are those arising in the central nervous system (CNS). Medulloblastomas occur in the cerebellum and are the most common malignant paediatric brain tumours ([@bib11]). Over recent years, treatments have improved with 5-year survival rates for patients with medulloblastoma of 60--70% ([@bib31]). However, one third of patients still die and many surviving patients suffer long-term side effects from treatments ([@bib17]).

Recent expression array studies have identified subgroups of medulloblastoma associated with different molecular pathways ([@bib50]; [@bib25]; [@bib38]). One subgroup was characterised by aberrant activation of the WNT/*β*-catenin pathway. Additional studies have identified WNT/*β*-catenin pathway activation in 25% medulloblastomas with the majority associated with activating mutations in *β*-catenin ([@bib12]; [@bib8]; [@bib14]; [@bib42]). Pathway activation has also been shown to be associated with a better clinical outcome ([@bib12]; [@bib14]).

The WNT/*β*-catenin pathway plays a key role in many cellular functions related to tumorigenesis including cell proliferation, migration and differentiation. *β*-Catenin is the key downstream effecter. When the pathway is inactive, *β*-catenin is bound to a cytoplasmic complex containing adenomatous polyposis coli, axin1 and glycogen synthase kinase 3*β*. Glycogen synthase kinase 3*β* phosphorylates *β*-catenin which targets the protein for degradation through the ubiquitin-proteasome system ([@bib37]). Upon pathway activation, the cytoplasmic complex is inhibited stabilising *β*-catenin and allowing it to translocate to the nucleus where it acts as a transcriptional cofactor of TCF and LEF and leads to the transcription of target genes including myc (*MYC*) and cyclin D1 (*CCND1*) ([@bib20]; [@bib48]). In the majority of medulloblastoma cases, WNT/*β*-catenin pathway activation is caused by mutations in *β*-catenin that are thought to disrupt the phosphorylation sites that target the protein for degradation ([@bib12]; [@bib8]; [@bib14]).

The WNT/*β*-catenin pathway plays a key role in CNS development including the cerebellum. Loss of Wnt1 or *β*-catenin in mouse models caused severe abnormalities in midbrain and cerebellar development by preventing specification of the midbrain--hindbrain boundary ([@bib33]; [@bib49]; [@bib45]). The pathway also regulates stem cell proliferation ([@bib6]; [@bib23]), and the balance between progenitor cell expansion and differentiation ([@bib55]).

The cell of origin of medulloblastoma has long been debated. Cerebellar neurons are generated from two progenitor cell zones, the cerebellar ventricular zone (VZ) and the rhombic lip (RL) ([@bib34]). Granule neurons originate from the RL. The majority of other cerebellar neurons, as well as glial cells, originate from the VZ ([@bib18]). Medulloblastomas were thought to arise from progenitors of granule neurons found in the external granule layer of the cerebellum ([@bib31]). However, researchers have suggested that different subtypes of medulloblastoma arise from distinct progenitor cells, with WNT/*β*-catenin pathway subgroup tumours originating from progenitor cells in the VZ ([@bib24]; [@bib31]; [@bib17]; [@bib47]). In a recent study by [@bib16], tumours were generated from dorsal brain stem progenitor cells in the lower RL in a mouse model of WNT/*β*-catenin pathway associated medulloblastoma.

The biological effect of WNT/*β*-catenin pathway activation in medulloblastoma is unknown. Pathway activation has been associated with a better prognosis, which could suggest activation is a disadvantage for the tumour. However, it seems unlikely a tumour would retain cells with an activating mutation unless it played some role in tumorigenesis. We hypothesised that pathway activation plays a fundamental role in tumorigenesis. To understand the role of WNT/*β*-catenin pathway activation in medulloblastoma, we stably expressed Wnt1, to activate the WNT/*β*-catenin pathway, in Myc immortalised cerebellar progenitor cells ([@bib46]). We show that WNT/*β*-catenin pathway activation enables tumours to form *in vivo* and propose that WNT/*β*-catenin pathway does this by inhibiting the ability of the cells to differentiate, thereby maintaining them in their proliferative state. We found expression of nerve growth factor receptor (NGFR) was downregulated in the Wnt1-expressing cell line. Signalling through NGFR, by nerve growth factor (NGF), can induce neuronal differentiation, suggesting downregulation of NGFR expression could be one mechanism by which WNT/B-catenin pathway activation inhibited differentiation. Analysis of cerebellar progenitor cell markers suggested the C17.2 line did not resemble granule cell progenitors, supporting evidence that medulloblastomas with WNT/*β*-catenin pathway activation do not originate from the external granule layer.

Materials and Methods
=====================

Stable cell line generation
---------------------------

The pCA-EGFP vector was used to generate a Wnt1 expression clone. EGFP was removed and Wnt1 cDNA was cloned into the vector. The C17.2 cell line generated from mouse cerebellar progenitor cells ([@bib46]) was stably transfected with the Wnt1 expression construct. Cells expressing Wnt1 were selected using 2 mg ml^−1^ of zeocin (Invitrogen, Carlsbad, CA, USA).

Cell culture conditions
-----------------------

C17.2 cells were cultured in standard humidified incubators at 5% CO~2~ in Dulbecco\'s modified Eagle\'s medium/ℒ-glutamine (Invitrogen) supplemented with 10% fetal bovine serum (PAA Laboratories, Yeovil, UK), 5% horse serum (Invitrogen) and antibiotics. Under differentiation conditions, the media above was replaced with neurobasal medium (Invitrogen) containing B27 supplement (Invitrogen), 2 mℳℒ-glutamine (Sigma-Aldrich, Poole, UK) and NGF (Millipore, Watford, UK) at a final concentration of 200 ng ml^−1^. For the Wnt1 stable cell line, media was supplemented with 0.5 mg ml^−1^ of zeocin (Invitrogen). For calculation of cell doubling times in low-serum conditions, 2% serum was used.

RT--PCR
-------

Independent samples were taken from cell lines for analysis. RNA was extracted from snap-frozen cell pellets using the *mir*Vana miRNA Isolation kit (Invitrogen), following the manufacturers\' instructions. After extraction, 1 *μ*g of each RNA sample was treated with 2 U DNAse and incubated at 37 °C for 15 min followed by 10 min at 65 °C. cDNA synthesis was carried out using the Revertaid cDNA synthesis kit (Fermentas, St Leon-Rot, Germany). Briefly, 500 ng of RNA was incubated with 200 U reverse transcriptase and 500 ng of OligodT primer at 42 °C for 1 h followed by 70 °C for 5 min. Twenty units of RiboLock RNase inhibitor was also included in the reaction mix.

Primers used for PCR are displayed in [Table 1](#tbl1){ref-type="table"}. One microliter of cDNA was incubated with 1 × Biomix Red, and forward and reverse primers (1 nℳ) in a final volume of 10 *μ*l. The PCR conditions were: 95 °C for 10 min followed by 40 cycles of 95 °C for 30 s, optimised primer annealing temperature for 1 min and 72 °C for 1 min. Products were visualised by electrophoresis through a 2% agarose gel at 120 V for 30 min. For primers using a touchdown programme the annealing temperature was decreased by 1 °C each cycle for the first 10 cycles, starting from 65 °C. *GAPDH* was used as a housekeeping gene in all experiments.

Quantitative PCR
----------------

Quantitative PCR reactions were carried out as previously described ([@bib41]). Primer sequences and optimised annealing temperatures are given in [Table 1](#tbl1){ref-type="table"}. Three independent cDNA samples from each cell line were used for each analysis. Data was normalised using *Gapdh*. Relative expression compared to one C17.2 cDNA sample was calculated using the Pfaffl equation ([@bib40]).

Immunofluorescence
------------------

Cells were fixed by incubating with 4% PFA for 20 min. Cells were washed 3 × 5 min in PBST (PBS, 0.1% Tween). Cells were permeabilised and blocked in 5% normal goat serum (NGS, Invitrogen) and 0.25% Triton X-100 in PBS at room temperature for 1 h. Cells were washed in PBST for 3 × 5 min. Primary antibodies were prepared in 2% NGS and 0.1% Triton X-100 in PBS. Cells were then incubated with the primary antibody at 4 °C overnight. The following antibodies were used; mouse anti-*β*-catenin (1 in 200, 2677 Cell Signaling Technology, Danvers, MA, USA) and rabbit anti-TUJ1 (1 in 500, Covance, Harrogate, UK). Cells were washed 3 × 5 min in PBST then incubated with the appropriate secondary antibody; Alexa Fluor 555 goat anti-mouse (1 in 500, Invitrogen) or Alexa Fluor 488 goat anti-rabbit antibody (1 in 500, Invitrogen) at room temperature for 1 h in the dark. After three further washes in PBST, cells were mounted using Vectashield containing 4′,6-diamidinophenylindole (Vector Laboratories, Peterborough, UK). Images were obtained using a Leica DMRM fluorescent microscope (Nikon, Digital sight-USB (H), Kingston upon Thames, UK) equipped with a Nikon digital camera. NIS elements software was used to capture images (Nikon).

Western blot
------------

Western blotting was carried out as previously described ([@bib29]). Membranes were incubated with primary antibodies to Wnt1 (1 in 500, Abcam, Cambridge, UK), Ngfr (1 in 1000, Cell Signaling Technology) and Gapdh (1 in 100, Abcam) for 1 h at room temperature.

Intracranial injection of cells into rats
-----------------------------------------

Adult male Sprague-Dawley rats were housed with libitum access to food and water at a 12-h light/dark cycle. Animals were treated according to the guidelines of the European Community and local ethics committee. The animals were immune suppressed using cyclosporine A (10 mg kg^−1^ per day). Cells at 85--90% confluence were prepared for transplantation and stored on wet ice. Animals were anesthetised with isofluorane (1--2.5% in an oxygen/70% nitrous oxide mixture) and stereotaxically injected with 1 *μ*l of cell suspension (200 000 cells *μ*l^−1^) at two sites directly overlying the substantia nigra. Cells were injected slowly through a 22-guage, 10 *μ*l Hamilton syringe, and the needle was left in place for 2 min after completion of injection. For each cell line, four animals were transplanted. After 8 weeks, brains were excised. Frozen sections were cut and stained with haematoxylin and eosin for subsequent review by a pathologist.

Immunohistochemistry
--------------------

The following antibodies were used; rabbit anti-Ki-67 (SP6) (1 in 200, Neomarkers, Fremont, CA, USA), rabbit anti-*β*-catenin (1 in 250, 9582 Cell Signaling Technology) and rabbit anti-Myc (1 in 100, Abcam). Antigen retrieval was performed by incubating sections in sodium citrate buffer (pH 6) in a steamer for 40 min. Endogenous protein was blocked by incubating with 5% NGS for 10 min. Sections were then incubated with a peroxidase block (Dako, Ely, UK) for 5 min. Ki-67 and *β*-catenin antibodies were incubated at 4 °C overnight. Myc antibody was incubated for 1 h at room temperature. Detection was undertaken using the EnVision detection system peroxidase/DAB (Dako). Stained sections were reviewed by a pathologist.

Electron microscopy
-------------------

Frozen sections were fixed in 2.5% glutaraldehyde in cacodylate buffer for 24 h followed by 1% osmium tetroxide for 1 h. This was followed by standard EM processing using TAAB TER resin, then inverting a resin-filled capsule over the section on the slide before polymerisation at 65 °C overnight. The subsequent resin block containing the section was removed from the glass slide and trimmed. A 0.5-*μ*m section was cut using a Leica UM7 ultramicrotome before staining with toluidine blue in 1% borax (Leica Microsystems, Milton Keynes, UK). Slides were examined using a light microscope and an area selected for electron microscopy. Eighty nanometer sections were cut from the selected area and mounted on a copper grid and stained with uranyl acetate in ethanol followed by lead citrate. The stained sections were examined in a JEOL 1010 transmission electron microscope at 100 KV and appropriate images recorded using an integrated digital camera system (Olympus-SIS, Munster, Germany).

Results
=======

Construction of a cerebellar progenitor cell line with stable WNT/*β*-catenin pathway activation
------------------------------------------------------------------------------------------------

We used a cerebellar progenitor cell line (C17.2) immortalised by stable expression of Myc ([@bib46]) to investigate the role of the WNT/*β*-catenin pathway activation in medulloblastoma. Pathway activation was induced by constructing a cell line with stable expression of Wnt1. Wnt1 cDNA was cloned into the pCA-EGFP vector and then transfected into the C17.2 cells. Multiple clones of cells were isolated. The stable Wnt1-expressing cell line (C17.2-Wnt1) selected for further analysis did not show abnormal morphology or cell growth rate compared with the other Wnt1 lines. Stable Wnt1 expression was confirmed by RT--PCR and western blot ([Figures 1A and B](#fig1){ref-type="fig"}). No *Wnt1* gene or protein expression was seen in the original C17.2 line. *Myc* gene expression was retained in the C17.2-Wnt1 cell line with no significant difference in expression level compared with C17.2 ([Figure 1C](#fig1){ref-type="fig"}). The morphology of C17.2-Wnt1 was slightly altered relative to C17.2. The C17.2 cell line changed in appearance during culture, sometimes looking epithelial ([Figure 1D](#fig1){ref-type="fig"}) and sometimes displaying cell processes ([Figure 1E](#fig1){ref-type="fig"}). The C17.2-Wnt1 line looked uniformly epithelial with a more rounded cell shape compared with C17.2 ([Figure 1F](#fig1){ref-type="fig"}). To demonstrate Wnt1 expression activated the WNT/*β*-catenin pathway, we initially looked at the expression of the pathway target *Axin2* by RT--PCR. Expression was only seen in the C17.2-Wnt1 line ([Figure 1A](#fig1){ref-type="fig"}). We also analysed the intra-cellular location of *β*-catenin. Upon pathway activation, *β*-catenin is stabilised and translocates to the nucleus to induce transcription of target genes. Nuclear localisation of *β*-catenin was only seen in C17.2-Wnt1 ([Figure 1G](#fig1){ref-type="fig"}).

Functional effect of WNT/*β*-catenin pathway activation
-------------------------------------------------------

We investigated the functional effect of WNT/*β*-catenin pathway activation *in vitro* to try to gain an understanding of what role pathway activation is playing in tumorigenesis. We investigated cell proliferation by calculating doubling times in low- and high-serum conditions. However, we found no significant difference between the two cell lines (data not shown). We also investigated cell migration using a scratch assay but again saw no difference in the presence or absence of WNT/*β*-catenin pathway activation (data not shown).

We looked at the cells\' ability to undergo neuronal differentiation by culturing the cells in differentiation media, containing NGF. After 1 day, C17.2 cells differentiated into neurons. However, even after 7 days, the C17.2-Wnt1 cell line had not differentiated ([Figures 2A--D](#fig2){ref-type="fig"}). We investigated this further by staining fluorescently for the neuronal marker beta-tubulin (Tuj1). C17.2 cells grown in normal or differentiation culture media displayed expression of Tuj1, with the differentiated cells displaying a higher intensity signal. The C17.2-Wnt1 cells displayed no staining under either condition ([Figure 2E](#fig2){ref-type="fig"}).

To investigate further the role the WNT/*β*-catenin pathway is having in the decision to undergo differentiation, we investigated the expression of a number of genes involved in neuronal differentiation. To stimulate differentiation in culture, we used NGF. We therefore looked at the expression of the two receptors of this protein; Ngfr and neurotrophic tyrosine kinase receptor type 1 (Ntrk1). Gene expression of *Ntrk1* was not seen in either cell line (data not shown). Nerve growth factor receptor (*Ngfr*) gene expression was seen in C17.2; however, expression was decreased in C17.2-Wnt1 ([Figure 2F](#fig2){ref-type="fig"}). Nerve growth factor receptor (Ngfr) protein expression was seen in C17.2 but was lost in C17.2-Wnt1 ([Figure 2G](#fig2){ref-type="fig"}).

Cells with WNT/*β*-catenin pathway activation form tumours *in vivo*
--------------------------------------------------------------------

C17.2 and C17.2-Wnt1 cells were injected orthotopically into immunosupressed rats. As previously published ([@bib46]), C17.2 cells did not form tumours. However, with induced WNT/*β*-catenin pathway activation (C17.2-Wnt1 cells), tumours rapidly formed after 4 weeks. All four rats transplanted with C17.2-Wnt1 cells developed tumours. Histologically, tumours resembled primitive neuroectodermal tumours (PNETs), consistent with the appearance of classical medulloblastoma. Tumours were well circumscribed with no infiltration into the surrounding brain tissue ([Figures 3A and B](#fig3){ref-type="fig"}). Ki67 staining revealed a high proliferation rate similar to that seen in medulloblastoma ([Figure 3C](#fig3){ref-type="fig"}). *β*-Catenin staining revealed nuclear localisation of the protein, suggesting the WNT/*β*-catenin pathway was active *in vivo*, as well as *in vitro* ([Figure 3D](#fig3){ref-type="fig"}). Tumours also displayed Myc protein expression ([Figure 3E](#fig3){ref-type="fig"}). Electron microscopy was used to look for features of differentiation. Very few features of neuronal differentiation such as neurosecretory vesicles were seen, consistent with a PNET ([Figures 3F and G](#fig3){ref-type="fig"}). Our results demonstrated that cerebellar progenitor cells with stable Myc expression and WNT/*β*-catenin pathway activation became tumorigenic.

C17.2 cells express stem cell markers of the cerebellar VZ
----------------------------------------------------------

To investigate the cell of origin of medulloblastomas with WNT/*β*-catenin pathway activation, we looked at what cell type C17.2 cells resemble. We analysed the expression levels of genes that have been linked to different cerebellar progenitor cell types using RNA extracted from cells grown in normal or differentiation media using RT--PCR. For granule cell progenitors, we investigated *Atoh1* and *Cntn2* ([@bib3]; [@bib1]; [@bib4]), whereas *ptf1a*, *Meis1* and *Lhx2* were used as markers of cells in the cerebellar VZ ([@bib22]; [@bib36]; [@bib34]). We also investigated the neural stem cell marker *Sox2* and the post mitotic marker of Purkinje cells *Calb1* ([@bib52]).

Expression was only seen for *Ptf1a*, *Meis1* and *Sox2*, suggesting the C17.2 cells are more like stem cells found in the VZ than granule cell progenitors in the RL. *Ptf1a* expression was seen in a subset of samples from C17.2 but not in C17.2-Wnt1 ([Figure 4A](#fig4){ref-type="fig"}). During culture, the appearance of C17.2 varied sometimes appearing more differentiated and sometimes more epithelial. This variation may have influenced when *Ptf1a* expression was seen. *Meis1* and *Sox2* expression was seen in all samples analysed from both cell lines. Quantitative PCR revealed that *Meis1* displayed a similar level of gene expression in both cell lines ([Figure 4B](#fig4){ref-type="fig"}). *Sox2* gene expression was four-fold higher in C17.2 compared with C17.2-Wnt1 ([Figure 4B](#fig4){ref-type="fig"}). No expression was seen for *Atoh1* or *Cntn1*, suggesting, in this model, the cells generating tumours did not resemble granule cell progenitors.

Discussion
==========

We have generated a cell line with the means to orthotopically model medulloblastoma with WNT/*β*-catenin pathway activation. Previous studies have demonstrated that tumours with WNT/*β*-catenin pathway activation account for 25% of medulloblastomas. However, the role pathway activation is playing in the development of these tumours is not understood. Therefore, it is important to generate models that can be used to study the pathology of this disease and as a resource for developing and testing new treatments. We provide evidence of the role the WNT/*β*-catenin pathway may be having in medulloblastoma. Our data suggest pathway activation is contributing to tumorigenesis by inhibiting neuronal differentiation of progenitor cells therefore maintaining them in a proliferative and more 'stem-like\' state.

Aberrant activation of the WNT/*β*-catenin pathway in a subset of medulloblastomas has been demonstrated in a number of studies ([@bib12]; [@bib8]; [@bib50]; [@bib42]). However, the biological effect of pathway activation and how this influences tumorigenesis is still unknown. Pathway activation in medulloblastoma has also been shown to be associated with a better prognosis, suggesting it is a disadvantage to the tumour ([@bib12]; [@bib14]). However, we hypothesised that the pathway is involved in the development of medulloblastoma and that therefore the reason for the association with a better prognosis is that this subgroup is less aggressive or more susceptible to current treatments than other medulloblastomas with different molecular aberrations.

We demonstrated that WNT/*β*-catenin pathway activation in cerebellar progenitor cells caused the cells to form tumours *in vivo* that histologically resembled classical medulloblastoma, confirming our hypothesis that pathway activation is involved in tumorigenesis. In our model, pathway activation may be working in conjunction with Myc, as the gene is stably expressed in the C17.2 cell line and protein expression was retained in tumours generated *in vivo*. Previously reported data has shown that MYC expression is seen in medulloblastomas with WNT/*β*-catenin pathway activation ([@bib25]; [@bib38]), suggesting our model is representative of this clinical subgroup. Analysis of previously published medulloblastoma expression array data ((GSE10237) ([@bib25])) demonstrated that tumours with WNT/*β*-catenin pathway activation displayed a significantly higher level of Myc expression compared with the rest of the tumours (*P*=0.006), suggesting the two may cooperate in patient tumours ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). In a mouse model of CNS PNET, *β*-catenin mutations alone did not induce tumour formation. However, in combination with Myc expression and p53 knockout tumours developed ([@bib35]).

In our model, WNT/*β*-catenin pathway activation inhibited neuronal differentiation *in vitro*. The WNT/*β*-catenin pathway plays a complex role in CNS development. WNT/*β*-catenin pathway signals are involved in the positioning of the cerebellum along the anterior--posterior axis of the neural tube ([@bib44]). The pathway has also been shown to influence the decision of neuronal progenitor cells to proliferate or differentiate. At different developmental stages, pathway activation has either been shown to stimulate proliferation or differentiation ([@bib6]; [@bib51]; [@bib55]; [@bib23]). In the majority of studies, pathway activation was found to stimulate progenitor cell proliferation at early development stages and neuronal differentiation during later stages ([@bib21]). Less is known about how the WNT/*β*-catenin pathway specifically affects progenitor cells in the cerebellum. However, a recent study demonstrated that WNT/*β*-catenin pathway activation promoted proliferation and impaired differentiation of neural stem cells in the developing cerebellum ([@bib39]).

Our data suggest the C17.2 cell line is derived from progenitor cells at a stage in development when they are prevented from differentiating in response to WNT/*β*-catenin pathway signals. These findings suggest that activation of WNT/*β*-catenin pathway in our model may be causing tumour formation by preventing differentiation and maintaining the cells in a more primitive, proliferating state. We saw no difference in the rate of proliferation between C17.2 and C17.2-Wnt1 cells. This may be due to the fact that the C17.2 cell line was originally immortalised using Myc. We suggest that myc stimulates proliferation of the cells and WNT/*β*-catenin pathway activation prevents the cells from responding to signals to differentiate. Similarly, in a mouse model of CNS PNET, induced by WNT/*β*-catenin pathway activation in conjunction with Myc expression and p53 knockout, tumours displayed regions of differentiation, but not in cells displaying nuclear *β*-catenin, indicating pathway activation inversely correlated with differentiation ([@bib35]).

Analysis of medulloblastoma expression array data revealed that genes displaying differential expression between the WNT/*β*-catenin pathway subgroup and other medulloblastomas included a number of genes linked to neuronal differentiation. This included upregulation of the fetal growth factor *FGF20* and the epidermal growth factor receptor *ERBB2*, and downregulation of the neuronal marker *MAP2* in the WNT subgroup ([@bib25]; [@bib38]). Additionally, a recent study has shown increased expression of neuronal markers in medulloblastoma xenografts treated with drugs that can inhibit the WNT/*β*-catenin pathway ([@bib7]).

We saw a downregulation of Ngfr expression in C17.2-Wnt1 cells compared with C17.2. Nerve growth factor can bind to two different cell receptors; NGFR and the tyrosine kinase NTRK1. Signalling through NGFR has been shown to stimulate many different responses including survival, differentiation and apoptosis ([@bib13]; [@bib28]; [@bib10]; [@bib32]). Nerve growth factor receptor is highly expressed on neurons and glia during CNS development ([@bib9]). Neonatal NGFR-positive neural stem cells have been shown to have neurogenic potential that was enhanced by treatment with neurotrophins including NGF. However, this enhancement was not seen using stem cells from NGFR^−/−^ mice ([@bib54]). Nerve growth factor receptor is expressed in the developing cerebellum; however, its\' role is not fully understood ([@bib2]).

Nerve growth factor receptor expression has also been seen in medulloblastoma. However, expression was not seen in medulloblastomas with WNT/*β*-catenin pathway activation ([@bib25]; [@bib2]). Analysis of previously published mRNA array expression data ((GSE10237) ([@bib25])) demonstrated WNT subgroup tumours displayed a low level of NGFR expression compared with the rest of the tumour cohort ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). Nerve growth factor receptor expression has also shown higher expression in desmoplastic compared with classic medulloblastoma ([@bib5]; [@bib26]). Consistent with these histological findings, WNT/*β*-catenin pathway activation has more frequently been seen in classic medulloblastomas and sonic hedgehog (Shh) pathway activation in desmoplasic tumours ([@bib50]).

No expression of the second receptor to NGF, Ntrk1, was seen in C17.2 or C17.2-Wnt1. Therefore, a loss of Ngfr expression in C17.2-Wnt1 means they lack any receptor to respond to NGF signals, which may explain the lack of neuronal differentiation seen in response to NGF treatment. As far as we are aware there is no evidence in the literature linking the WNT/*β*-catenin pathway to NGFR expression. Further investigation is needed to determine if the downregulation of expression seen in the C17.2-Wnt1 cells is a direct consequence of WNT/*β*-catenin signalling.

There has been much debate about the cell of origin of medulloblastoma. In the cerebellum, there are two distinct zones of progenitor cells; the VZ and the RL. The main type of cells generated from the RL are granule neurons with the majority of other cell types arising from the VZ ([@bib18]). Medulloblastomas have been suggested to arise from granule cell precursors. However, genomic and expression data from medulloblastomas suggested that not all subtypes arise from these cells ([@bib17]; [@bib47]). A more current interpretation proposes that medulloblastomas with WNT/*β*-catenin pathway activation may arise from progenitor cells in the VZ. In support of this hypothesis, aberrant activation of the WNT/*β*-catenin pathway induced proliferation and inhibited differentiation of neural stem cells from the cerebellar VZ but not granule progenitor cells ([@bib39]). In a separate study, selected depletion of adenomatous polyposis coli in ATOH1-expressing cells lead to a decrease in cell proliferation and premature differentiation of cerebellar granule cells ([@bib30]).

The lack of expression of granule cell markers Atoh1 and Cntn2 in both the C17.2 and C17.2-Wnt1 lines suggests the C17.2 cells did not resemble this lineage. The bHLH factor Ptf1a is essential for the generation of GABAergic neurons from the cerebellar VZ ([@bib22]). C17.2 cells demonstrated expression of Ptf1a, suggesting the cells resembled VZ cells more than granule cell progenitors. This was supported by the expression of Meis1, which has been shown to be expressed by cells in the VZ ([@bib36]). The original C17.2 cell line was developed from cerebella of newborn mice (P4) ([@bib43]). At this stage of development, dividing granule cell progenitors are present in the RL. Neural stem cells, which originated in the VZ, are also present in the white matter ([@bib27]). Therefore, the C17.2 line could have been generated from the neural stem cells rather than granule progenitor cells. However, it cannot be discounted that the immortalisation of the C17.2 cells with Myc may have affected the phenotype of the original cells the line was derived from, as Myc also plays a role in normal neuronal development ([@bib19]; [@bib53]). It has also previously been demonstrated that immortalisation of granule cell precursors with SV40 T antigen caused the cells to lose their restricted fate and gain an ability to differentiate into multiple cell types ([@bib15]). Hence, it cannot be discounted that the original cells the C17.2 line was generated from could have been granule progenitor cells that were altered by Myc immortalisation.

The gene expression of cerebellar markers seen in C17.2 and C17.2-Wnt1 cells reflects what is seen in WNT subgroup medulloblastomas ((GSE10237) ([@bib25])). High *Atoh1* and *Cntn2* expression was seen in Shh sub-group tumours, but not in the WNT/*β*-catenin group. *Meis1* expression was seen in both WNT and Shh groups. *Sox2* displayed higher expression in the Shh group ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). *Ptf1a* data was not available.

In the study by [@bib16], tumours resembling medulloblastoma were generated in mice with mutated *β*-catenin and p53 knockout. In this model, no tumours developed from cerebellar progenitors but instead arose from brain stem progenitor cells found in the lower RL. This region lines the ventral region of the fourth ventricle, with the cerebellum located on the dorsal side. They also found that the normal migration and differentiation of these cells was impaired in the tumour model, agreeing with the inhibition of neuronal differentiation we saw in our study. In the model developed by Gibson *et al*, tumours developed from a combination of WNT/*β*-catenin pathway activation and TP53 knockout in contrast to our model, where Myc expression was used which may explain why they did not see tumours develop from cerebellar progenitor cells. In addition, considering the complex role the WNT/*β*-catenin pathway has in CNS development, the timing of induced pathway activation may be important in determining where tumours arise. In a recent study, a transient increase in proliferation and disruption of normal cerebellar development occurred in neural stem cells from the cerebellar VZ when the WNT/*β*-catenin pathway was aberrantly activated, suggesting at least some WNT subgroup tumours may develop from cerebellar progenitors ([@bib39]).

In conclusion, we have developed a cell line that provides the means to orthotopically model WNT/*β*-catenin pathway-activated medulloblastoma. We suggest that inhibition of progenitor cell differentiation, therefore maintaining them in a proliferative and more 'stem-like\' state, is the mechanism by which pathway activation is involved in tumorigenesis, which in turn may be achieved through downregulated expression of NGFR. This evidence suggests pathway activation is playing a key role in tumour development and is therefore an important treatment target for this subset of medulloblastomas. Our data also demonstrates that progenitor cells expressing stem cell markers of the cerebellar VZ have the potential to develop tumours that resemble medulloblastoma. As tumours with WNT/*β*-catenin pathway activation account for 25% of medulloblastomas, understanding how the pathway is involved in tumorigenesis is important. This model can be used as a resource for future analysis of the role the pathway is playing in tumorigenesis and also for the development and testing of targeted therapies.
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![Characterisation of C17.2 and C17.2-Wnt1 cell lines. *Wnt1* gene and protein expression was confirmed in C17.2-Wnt1 by RT--PCR and western blot, respectively (**A** and **B**). WNT/*β*-catenin pathway activation in C17.2-Wnt1 was confirmed by *Axin2* expression. Expression of the WNT/*β*-catenin pathway target *Axin2* was only seen in the C17.2-Wnt1 line (**A**). The housekeeping gene *Gapdh* demonstrated similar gene and protein expression levels in both C17.2 and C17.2-Wnt1 (**A** and **B**). Three repeats generated from independent samples are displayed for each cell line; C1, C2 and C3 from C17.2 and W1, W2, W3 from C17.2-Wnt1. *Myc* gene expression was not altered after Wnt1 expression in the C17.2 cell line as measured by qPCR (**C**). Stable overexpression of Wnt1 altered the morphology of the cells. The appearance of C17.2 was sometimes epithelial (**D**) and sometimes displayed cell processes (**E**). C17.2-Wnt1 was uniformly epithelial with a more rounded cell shape compared with C17.2 (**F**). The cellular location of *β*-catenin was investigated using immunofluorescence. In C17.2, only membrane and cytoplasmic staining of *β*-catenin was seen. In C17.2-Wnt1, nuclear staining, indicating pathway activation, was also seen (**G**). Abbreviation: Neg=negative control.](bjc2012377f1){#fig1}

![WNT/*β*-catenin pathway activation inhibits neuronal differentiation. Cells were grown in normal growth media (GM) or differentiation media (DM). After 1 day in DM, C17.2 cells lost the epithelial morphology seen when in GM (**A**) and gained a neuronal appearance (**B**). C17.2-Wnt1 retained the same appearance in GM (**C**) or DM (**D**) with no evidence of neuronal differentiation. C17.2 cells displayed some TUJ1 staining in GM with an increased intensity of staining when the cells underwent neuronal differentiation in DM. C17.2-Wnt1 cells displayed no TUJ1 staining under growth or differentiation conditions (**E**). Nerve growth factor receptor (*Ngfr*) gene expression was analysed in three independent samples from C17.2 and C17.2-Wnt1 by RT--PCR. Nerve growth factor receptor expression was seen in C17.2 (C1--C3). No expression or a very low level of expression was seen in C17.2-Wnt1 (W1-W3) (**F**). Expression of the housekeeping gene *Gapdh* was seen in all samples. Nerve growth factor receptor protein expression, measured by western blot, was seen in C17.2 (C1, C2) but lost in C17.2-Wnt1 (W1, W2) (**G**). Protein expression of Gapdh was seen in all samples. Abbreviation: Neg=negative control.](bjc2012377f2){#fig2}

![C17.2-Wnt1 cells formed tumours *in vivo*. Hematoxylin and eosin staining shows a tumour similar in appearance to a PNET. Tumours were well circumscribed with no infiltration into the surrounding brain tissue (**A** and **B**). Ki67 staining revealed a proliferation rate in the tumours similar to those seen in medulloblastoma (**C**). Nuclear localisation of *β*-catenin was seen in the tumours, indicating WNT/*β*-catenin pathway activation (**D**). Tumours also displayed myc protein expression (**E**). Electron microscopy revealed very few features of differentiation such as neurosecretory vesicles (red arrow) (**F** and **G**). Features were consistent with a PNET.](bjc2012377f3){#fig3}

![Gene expression of cerebellar progenitor markers. Expression was analysed in samples extracted from cells grown in normal growth media (C17.2; C1-4, C17.2-Wnt1; W1-4) and cells grown in differentiation media (C17.2; Cd1-2, C17.2-Wnt1; Wd1-2). *Ptf1a* expression was seen in a subset of C17.2 cells measured by RT--PCR (**A**). Expression of the housekeeping gene gapdh was seen in all samples. *Meis1* and *Sox2* expression was seen in all samples analysed from both cell lines. Quantitative PCR revealed equal expression of *Meis1* in C17.2 and C17.2-Wnt1 cell lines. *Sox2* displayed four-fold higher expression in C17.2 compared with C17.2-Wnt1 (**B**). Abbreviation: Neg=negative control.](bjc2012377f4){#fig4}

###### Primers and optimised annealing temperatures for RT--PCR and qPCR

  *Primer*   *Forward sequence (5′--3′)*   *Reverse sequence (5′--3′)*    *Annealing temperature (°C)*
  ---------- ----------------------------- ----------------------------- ------------------------------
  Wnt1       CGACCTCGTCTACTTCGAG           ACCAGTGGAAGGTGCAGTTG                        58
  Axin2      CGCTCGGGTTTGTGTTAAGT          GAGAGCTGGAGCCCTCAATA                        58
  Myc        CCCCAAGGTAGTGATCCTCA          TCCAGCTCCTCCTCGAGTTA                        61
  Ngfr       CCTTGTGCTCGGTGGTATTT          AGAGACCCCCAGAACCAAAC                        58
  Ntrk1      AGAGCGATGTGTGGAGCTTT          TGATGGCGTAGACATCAGGA                    TD 65--55
  Atoh1      GACCCGCATTGGGTACTTTA          TGCATTGGCAGTTGAGTTTC                        58
  Cntn2      CTGGTTTTCTCGGGTGTGAT          GGGTCTTTTGCTGGGACATA                        58
  Sox2       AAGGGTTCTTGCTGGGTTTT          TGCCTTAAACAAGACCACGA                        61
  Lhx2       CTGCCACCTGGGCATCTC            AAGTGCAAGCGGCAATAGAC                    TD 65--55
  Meis1      TTATACCCAAGCCCAGATGC          ACTCATTGTCGGGTCTCCTG                        60
  Calb1      AGAAACGGCCAGAAACAGAA          TTGCCAAGAATCCAGAAACC                        58
  Ptf1a      CTTGCAGGGCACTCTCTTTC          CGATGTGAGCTGTCTCAGGA                        58
  Gapdh      ATGTTCGTCATGGGTGTGAA          GTCTTCTGGGTGGCAGTGAT                        58

Abbreviation: TD=touchdown.
